Live attenuated and inactivated viral vaccine formulation and nasal delivery: Potential and challenges

Tlaxca, José L.; Ellis, Scott; Remmele, Richard L.

doi:10.1016/j.addr.2014.10.002

Cited by 72 publications

(51 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recombinant influenza vaccine (RIV), like IIV, is administered intramuscularly and safely elicits a protective antibody response [32]. Live attenuated viruses have been used against numerous viral diseases in the past and continue to protect people today [36]. In contrast to IIV and RIV, live attenuated influenza vaccine (LAIV) mimics natural virus infection, which consequently has risks and benefits [37].…”

Section: Influenza a Virusmentioning

confidence: 99%

Downregulating Viral Gene Expression: Codon Usage Bias Manipulation for the Generation of Novel Influenza A Virus Vaccines

2015

View full text Add to dashboard Cite

Vaccination represents the best option to protect humans against influenza virus. However, improving the effectiveness of current vaccines could better stifle the health burden caused by viral infection. Protein synthesis from individual genes can be downregulated by synthetically deoptimizing a gene’s codon usage. With more rapid and affordable nucleotide synthesis, generating viruses that contain genes with deoptimized codons is now feasible. Attenuated, vaccine-candidate viruses can thus be engineered with hitherto uncharacterized properties. With eight gene segments, influenza A viruses with variably recoded genomes can produce a spectrum of attenuation that is contingent on the gene segment targeted and the number of codon changes. This review summarizes different targets and approaches to deoptimize influenza A virus codons for novel vaccine generation.

show abstract

Section: Influenza a Virusmentioning

confidence: 99%

Downregulating Viral Gene Expression: Codon Usage Bias Manipulation for the Generation of Novel Influenza A Virus Vaccines

2015

View full text Add to dashboard Cite

show abstract

“…In 2014, ASFV-specific antibodies were detected in piglets vaccinated with binary ethyleneimine (BEI)-inactivated ASFV Armenia08 strain in combination with the latest Polygen TM or Emulsigen ® -D adjuvant, but the strain failed to provide protection and acute clinical symptoms were quickly observed [ 44 ]. Inactivated vaccines are antigenic but lacked the capability to stimulate the body to produce complete cellular immune responses, which may be part of the reasons why inactivated vaccines cannot provide immune protection [ 45 ].…”

Section: Current State Of Asf Vaccine Developmentmentioning

confidence: 99%

Current State of Global African Swine Fever Vaccine Development under the Prevalence and Transmission of ASF in China

Liu

Wang

et al. 2020

Vaccines

View full text Add to dashboard Cite

African swine fever (ASF) is a highly lethal contagious disease of swine caused by African swine fever virus (ASFV). At present, it is listed as a notifiable disease reported to the World Organization for Animal Health (OIE) and a class one animal disease ruled by Chinese government. ASF has brought significant economic losses to the pig industry since its outbreak in China in August 2018. In this review, we recapitulated the epidemic situation of ASF in China as of July 2020 and analyzed the influencing factors during its transmission. Since the situation facing the prevention, control, and eradication of ASF in China is not optimistic, safe and effective vaccines are urgently needed. In light of the continuous development of ASF vaccines in the world, the current scenarios and evolving trends of ASF vaccines are emphatically analyzed in the latter part of the review. The latest research outcomes showed that attempts on ASF gene-deleted vaccines and virus-vectored vaccines have proven to provide complete homologous protection with promising efficacy. Moreover, gaps and future research directions of ASF vaccine are also discussed.

show abstract

“…The Ebola vaccines entering the clinic have all been formulated to remain stable at ultralow temperatures (-80°C), requiring maintenance of a cold chain that cannot be supported by standard refrigeration/freezer systems. Formulations of currently marketed biologics for nasal administration support stability at refrigerated and ambient temperatures [13,14]. Several formulations that support stability of recombinant adenoviruses (the platform of two of the vaccine candidates) for nasal administration have been described [15,16].…”

mentioning

confidence: 99%

A Respiratory Vaccine for Ebola: Close to a Reality?

Jonsson-Schmunk

Croyle²

2015

Future Virol.

View full text Add to dashboard Cite

Live attenuated and inactivated viral vaccine formulation and nasal delivery: Potential and challenges

Cited by 72 publications

References 107 publications

Downregulating Viral Gene Expression: Codon Usage Bias Manipulation for the Generation of Novel Influenza A Virus Vaccines

Downregulating Viral Gene Expression: Codon Usage Bias Manipulation for the Generation of Novel Influenza A Virus Vaccines

Current State of Global African Swine Fever Vaccine Development under the Prevalence and Transmission of ASF in China

A Respiratory Vaccine for Ebola: Close to a Reality?

Contact Info

Product

Resources

About